Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

DATA COMPILATION
#PharmaFlow

Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

Stock Recap
#PipelineProspector

Nocutil

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

59 API Suppliers, 19 USDMF, 13 CEP/COS, 2 JDMF, 3 EU WC, 10 KDMF, 30 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

358 FDF Dossiers, 55 FDA Orange Book, 255 Europe, 12 Canada, 12 Australia, 8 South Africa, 16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%, SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.004MG/ML, TABLET;ORAL - 0.1MG, TABLET;ORAL - 0.2MG, SPRAY, METERED;NASAL - 0.00083MG/SPRAY, SPRAY, METERED;NASAL - 0.00166MG/SPRAY, SPRAY, METERED;NASAL - 0.15MG/SPRAY, SPRAY, METERED;NASAL - 0.01MG/SPRAY, TABLET;SUBLINGUAL - 0.0277MG, TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 8 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 2 Cerata Pharmaceuticals LLP, 4 Dr. Paul Lohmann GmbH & Co. KGaA, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 15 BASF, 1 CD Formulation, 2 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 1 Gloria Interchem, 2 Ingredion Pharma Solutions, 12 Kerry, 10 Microlex e.U, 1 Neelkanth MineChem, 1 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Prachin Chemical, 7 Roquette, 5 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Sigachi Industries, 1 Silverline Chemicals, 1 Symrise, 2 Ulanqab Kema New Material, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Fillers, Diluents & Binders, 20 Disintegrants & Superdisintegrants, 19 Direct Compression, 18 Solubilizers, 17 Granulation, 13 Lubricants & Glidants, 13 Parenteral, 11 Thickeners and Stabilizers, 9 Chewable & Orodispersible Aids, 8 Co-Processed Excipients, 7 Emulsifying Agents, 7 Controlled & Modified Release, 6 Topical, 5 API Stability Enhancers, 5 Taste Masking, 5 Surfactant & Foaming Agents, 3 Coating Systems & Additives, 3 Film Formers & Plasticizers

DIGITAL CONTENT

33 News #PharmaBuzz

33 News #PharmaBuzz

GLOBAL SALES INFORMATION

18 US Medicaid Prescriptions, 24 Regulatory FDF Prices

MARKET PLACE

10 APIs, 8 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents, 14 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
31/03/2026	Anygen	South Korea	HLB Pep Co., Ltd.	20180905-209-J-198	Desmopressin acetate	2018-09-05	HLB Pep Co., Ltd.	South Korea	Test Production Building 2 (3-story building) within the Jeollanam-do Nano-Bio Center, 123, Namasandan-ro, Nam-myeon, Jangseong-gun, Jeollanam-do
31/03/2026	Hybio Pharmaceutical	China	SG Biochem Co., Ltd.	20181018-209-J-84	Desmopressin acetate	2018-10-18	Hybio Pharmaceutical Co., Ltd.	China	No.37, keji C.2nd Street. Shenzhen Hi-tech Industrial Park. Guangdong PRChina

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Nocutil

Nocutil

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

59 API Suppliers

19 USDMF

13 CEP/COS

2 JDMF

3 EU WC

10 KDMF

30 NDC API

19 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

358 FDF Dossiers

55 FDA Orange Book

255 Europe

12 Canada

12 Australia

8 South Africa

16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%

SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 0.004MG/ML

TABLET;ORAL - 0.1MG

TABLET;ORAL - 0.2MG

SPRAY, METERED;NASAL - 0.00083MG/SPRAY

SPRAY, METERED;NASAL - 0.00166MG/SPRAY

SPRAY, METERED;NASAL - 0.15MG/SPRAY

SPRAY, METERED;NASAL - 0.01MG/SPRAY

TABLET;SUBLINGUAL - 0.0277MG

TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma

8 Boai NKY Pharmaceuticals Ltd

3 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

3 Kirsch Pharma

2 Cerata Pharmaceuticals LLP

4 Dr. Paul Lohmann GmbH & Co. KGaA

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

15 BASF

1 CD Formulation

2 DFE Pharma

1 Finar

7 Gangwal Chemicals

1 Gloria Interchem

2 Ingredion Pharma Solutions

12 Kerry

10 Microlex e.U

1 Neelkanth MineChem

1 Nitika Pharmaceutical Specialities

2 Novo Excipients

2 Pharmatrans-Sanaq

4 Pluviaendo

1 Prachin Chemical

7 Roquette

5 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

3 Sigachi Industries

1 Silverline Chemicals

1 Symrise

2 Ulanqab Kema New Material

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Fillers, Diluents & Binders

20 Disintegrants & Superdisintegrants

19 Direct Compression

18 Solubilizers

17 Granulation

SPRAY, METERED;NASAL - 0.01MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons